Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling
{"title":"2024/25年中期流感疫苗有效性：8项欧洲研究，2024年9月至2025年1月","authors":"Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling","doi":"10.2807/1560-7917.ES.2025.30.7.2500102","DOIUrl":null,"url":null,"abstract":"<p><p>The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.</p>","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 7","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843620/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.\",\"authors\":\"Angela Mc Rose, Héloïse Lucaccioni, Kimberly Marsh, Freja Kirsebom, Heather Whitaker, Hanne-Dorthe Emborg, Amanda Bolt Botnen, Mark G O'Doherty, Francisco Pozo, Safraj Shahul Hameed, Nick Andrews, Mark Hamilton, Ramona Trebbien, Karina Lauenborg Møller, Diogo Fp Marques, Siobhan Murphy, Ross McQueenie, Jamie Lopez-Bernal, Simon Cottrell, Magda Bucholc, Esther Kissling\",\"doi\":\"10.2807/1560-7917.ES.2025.30.7.2500102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.</p>\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 7\",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843620/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European studies (17 countries) indicate an all-age influenza A VE of 32-53% in primary care and 33-56% in hospital settings, with some signals of lower VE by subtype and higher VE against influenza B (≥ 58% across settings). Where feasible, influenza vaccination should be encouraged and other prevention measures strengthened.
期刊介绍：
Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
